BD PharmingenTM FITC Mouse Anti-Human IFN-gamma

Description

Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma and calcium ionophore A23187 500 ng/ml final concentration; Sigma in the presence of GolgiStop 2 muM final concentration; Cat. No.554724 . The PBMC were stained with PE-Cy5 Mouse Anti-Human CD3 Cat.No. 555334/561007 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma Cat. No.555334/561057/552882 by using Pharmingens staining protocol left panel . The binding of FITC Mouse Anti-Human IFN-gamma was blocked by preincubation of cells with Purified Mouse Anti-Human IFN-gamma 5 mug; Cat. No. 554549; right panel . The quadrant markers for the bivariate dot plot were set based on the autofluorescence controls and verified using the unlabeled antibody and ligand blocking controls. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma and calcium ionophore A23187 500 ng/ml final concentration; Sigma in the presence of GolgiStop 2 muM final concentration; Cat. No.554724 . The PBMC were stained with PE-Cy5 Mouse Anti-Human CD3 Cat.No. 555334/561007 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma Cat. No.555334/561057/552882 by using Pharmingens staining protocol left panel . The binding of FITC Mouse Anti-Human IFN-gamma was blocked by preincubation of cells with Purified Mouse Anti-Human IFN-gamma 5 mug; Cat. No. 554549; right panel . The quadrant markers for the bivariate dot plot were set based on the autofluorescence controls and verified using the unlabeled antibody and ligand blocking controls. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma and calcium ionophore A23187 500 ng/ml final concentration; Sigma in the presence of GolgiStop 2 muM final concentration; Cat. No.554724 . The PBMC were stained with PE-Cy5 Mouse Anti-Human CD3 Cat.No. 555334/561007 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma Cat. No.555334/561057/552882 by using Pharmingens staining protocol left panel . The binding of FITC Mouse Anti-Human IFN-gamma was blocked by preincubation of cells with Purified Mouse Anti-Human IFN-gamma 5 mug; Cat. No. 554549; right panel . The quadrant markers for the bivariate dot plot were set based on the autofluorescence controls and verified using the unlabeled antibody and ligand blocking controls. Show More Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma and calcium ionophore A23187 500 ng/ml final concentration; Sigma in the presence of GolgiStop 2 muM final concentration; Cat. No.554724 . The PBMC were stained with PE-Cy5 Mouse Anti-Human CD3 Cat.No. 555334/561007 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma Cat. No.555334/561057/552882 by using Pharmingens staining protocol left panel . The binding of FITC Mouse Anti-Human IFN-gamma was blocked by preincubation of cells with Purified Mouse Anti-Human IFN-gamma 5 mug; Cat. No. 554549; right panel . The quadrant markers for the bivariate dot plot were set based on the autofluorescence controls and verified using the unlabeled antibody and ligand blocking controls. Show More Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma and calcium ionophore A23187 500 ng/ml final concentration; Sigma in the presence of GolgiStop 2 muM final concentration; Cat. No.554724 . The PBMC were stained with PE-Cy5 Mouse Anti-Human CD3 Cat.No. 555334/561007 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma Cat. No.555334/561057/552882 by using Pharmingens staining protocol left panel . The binding of FITC Mouse Anti-Human IFN-gamma was blocked by preincubation of cells with Purified Mouse Anti-Human IFN-gamma 5 mug; Cat. No. 554549; right panel . The quadrant markers for the bivariate dot plot were set based on the autofluorescence controls and verified using the unlabeled antibody and ligand blocking controls. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma and calcium ionophore A23187 500 ng/ml final concentration; Sigma in the presence of GolgiStop 2 muM final concentration; Cat. No.554724 . The PBMC were stained with PE-Cy5 Mouse Anti-Human CD3 Cat.No. 555334/561007 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC Mouse Anti-Human IFN-gamma Cat. No.555334/561057/552882 by using Pharmingens staining protocol left panel . The binding of FITC Mouse Anti-Human IFN-gamma was blocked by preincubation of cells with Purified Mouse Anti-Human IFN-gamma 5 mug; Cat. No. 554549; right panel . The quadrant markers for the bivariate dot plot were set based on the autofluorescence controls and verified using the unlabeled antibody and ligand blocking controls.